301103 何氏眼科
已收盘 12-20 15:00:00
资讯
新帖
简况
何氏眼科跌2.04% 2022年上市募13亿中原证券保荐
中国经济网 · 12-19 16:40
何氏眼科跌2.04% 2022年上市募13亿中原证券保荐
连亏两个季度!投资者多次喊话复刻“爱尔模式”,何氏眼科终于“听劝”?
市场资讯 · 12-13
连亏两个季度!投资者多次喊话复刻“爱尔模式”,何氏眼科终于“听劝”?
何氏眼科跌3.31% 2022年上市募13亿中原证券保荐
中国经济网 · 12-13
何氏眼科跌3.31% 2022年上市募13亿中原证券保荐
【私募调研记录】天算量化调研何氏眼科
证券之星 · 12-09
【私募调研记录】天算量化调研何氏眼科
何氏眼科:12月6日接受机构调研,北京英安私募、东北证券研究所等多家机构参与
证券之星 · 12-06
何氏眼科:12月6日接受机构调研,北京英安私募、东北证券研究所等多家机构参与
11月22日何氏眼科跌5.88%,融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 11-22
11月22日何氏眼科跌5.88%,融通健康产业灵活配置混合A/B基金重仓该股
何氏眼科(301103)11月21日主力资金净卖出402.52万元
证券之星 · 11-22
何氏眼科(301103)11月21日主力资金净卖出402.52万元
11月21日何氏眼科发布公告,其股东减持63.84万股
证券之星 · 11-21
11月21日何氏眼科发布公告,其股东减持63.84万股
何氏眼科:11月20日接受机构调研,中金银海(香港)基金、诺泉私募基金等多家机构参与
证券之星 · 11-20
何氏眼科:11月20日接受机构调研,中金银海(香港)基金、诺泉私募基金等多家机构参与
何氏眼科最新公告:股东先进制造基金计划减持公司股份不超过2%
证券之星 · 11-19
何氏眼科最新公告:股东先进制造基金计划减持公司股份不超过2%
何氏眼科(301103.SZ)股东先进制造基金拟减持不超2%股份
智通财经 · 11-19
何氏眼科(301103.SZ)股东先进制造基金拟减持不超2%股份
何氏眼科:11月12日接受机构调研,中信证券、长城基金等多家机构参与
证券之星 · 11-14
何氏眼科:11月12日接受机构调研,中信证券、长城基金等多家机构参与
11月7日何氏眼科涨5.15%,融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 11-07
11月7日何氏眼科涨5.15%,融通健康产业灵活配置混合A/B基金重仓该股
集采、价格战压力之下:华厦眼科白内障业务毛利率锐减 普瑞眼科、何氏眼科净利润遭脚踝斩
新浪证券 · 11-01
集采、价格战压力之下:华厦眼科白内障业务毛利率锐减 普瑞眼科、何氏眼科净利润遭脚踝斩
何氏眼科联合茅台招华发起一支健康科技产业基金
投资界 · 11-01
何氏眼科联合茅台招华发起一支健康科技产业基金
何氏眼科(301103)2024年三季报简析:净利润减83.53%,应收账款上升
证券之星 · 10-30
何氏眼科(301103)2024年三季报简析:净利润减83.53%,应收账款上升
何氏眼科:拟认缴出资2.4亿元,与茅台招华产业基金等合作设立投资基金
财经网 · 10-29
何氏眼科:拟认缴出资2.4亿元,与茅台招华产业基金等合作设立投资基金
何氏眼科(301103)9月30日股东户数1万户,较上期增加3.31%
证券之星 · 10-29
何氏眼科(301103)9月30日股东户数1万户,较上期增加3.31%
图解何氏眼科三季报:第三季度单季净利润同比减136.50%
证券之星 · 10-29
图解何氏眼科三季报:第三季度单季净利润同比减136.50%
何氏眼科(301103.SZ)发布前三季度业绩,净利润1637.55万元,下降83.53%
智通财经 · 10-29
何氏眼科(301103.SZ)发布前三季度业绩,净利润1637.55万元,下降83.53%
加载更多
公司概况
公司名称:
辽宁何氏眼科医院集团股份有限公司
所属行业:
卫生
上市日期:
2022-03-22
主营业务:
辽宁何氏眼科医院集团股份有限公司主营业务为面向眼病患者提供眼科专科诊疗服务和视光服务。公司的主要服务项目有白内障诊疗服务项目、屈光不正诊疗服务项目、玻璃体视网膜诊疗服务项目青光眼诊疗服务项目、干眼特色诊疗服务项目、中医特色诊疗服务项目。沈阳何氏眼科医院被评为“国家临床重点专科”、国际眼科理事会眼科专科医师培训基地、国家药物临床试验机构。
发行价格:
42.50
{"stockData":{"symbol":"301103","market":"SZ","secType":"STK","nameCN":"何氏眼科","latestPrice":22.4,"timestamp":1734678201000,"preClose":22.07,"halted":0,"volume":1143700,"delay":0,"floatShares":83090100,"shares":158000000,"eps":-0.1233,"marketStatus":"已收盘","marketStatusCode":5,"change":0.33,"latestTime":"12-20 15:00:00","open":22.18,"high":22.65,"low":22.07,"amount":25591900,"amplitude":0.0263,"askPrice":22.4,"askSize":35,"bidPrice":22.37,"bidSize":111,"shortable":0,"etf":0,"ttmEps":-0.1233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":22.07,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":24.28,"lowLimit":19.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":158026471,"pbRate":1.8,"roa":"--","roe":"0.8%","epsLYR":0.4022,"committee":0.441955,"marketValue":3540000000,"floatMarketCap":1861000000,"peRate":-181.67072,"changeRate":0.015,"turnoverRate":0.0138,"status":0},"requestUrl":"/m/hq/s/301103","defaultTab":"news","newsList":[{"id":"2492146602","title":"何氏眼科跌2.04% 2022年上市募13亿中原证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2492146602","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492146602?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:40","pubTimestamp":1734597600,"startTime":"0","endTime":"0","summary":" 何氏眼科于2022年3月22日在深交所创业板上市,公开发行股票3050.00万股,发行价格为42.50元/股,保荐人为中原证券股份有限公司,保荐代表人为钟坚刚、封江涛。 何氏眼科首次公开发行股票的发行费用总额为13,193.87万元,其中,保荐承销费用9,990.49万元。 何氏眼科披露的2021年度分红派息、转增股本实施公告显示,公司于2022年5月19日召开的2021年年度股东大会审议通过了《关于2021年度利润分配及资本公积金转增股本预案的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-12-19/doc-inczysvv6890231.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-19/doc-inczysvv6890231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0276","601375","BK0236","301103","BK0201"],"gpt_icon":0},{"id":"2491347281","title":"连亏两个季度!投资者多次喊话复刻“爱尔模式”,何氏眼科终于“听劝”?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491347281","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491347281?lang=zh_cn&edition=full","pubTime":"2024-12-13 18:02","pubTimestamp":1734084120,"startTime":"0","endTime":"0","summary":" 投资者提问何氏眼科。在连续两个季度出现亏损后,何氏眼科不仅话锋一变,对并购表现出积极态度,还于近期出资2.4亿元设立投资并购基金,真金白银投入并购扩张。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-13/doc-inczikpp2650414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2491979345","title":"何氏眼科跌3.31% 2022年上市募13亿中原证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2491979345","media":"中国经济网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491979345?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:16","pubTimestamp":1734077760,"startTime":"0","endTime":"0","summary":" 何氏眼科于2022年3月22日在深交所创业板上市,公开发行股票3050.00万股,发行价格为42.50元/股,保荐人为中原证券股份有限公司,保荐代表人为钟坚刚、封江涛。 何氏眼科首次公开发行股票的发行费用总额为13,193.87万元,其中,保荐承销费用9,990.49万元。 何氏眼科披露的2021年度分红派息、转增股本实施公告显示,公司于2022年5月19日召开的2021年年度股东大会审议通过了《关于2021年度利润分配及资本公积金转增股本预案的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-12-13/doc-inczieft9113117.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-13/doc-inczieft9113117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0236","BK0276","301103","BK0201","601375"],"gpt_icon":0},{"id":"2490211766","title":"【私募调研记录】天算量化调研何氏眼科","url":"https://stock-news.laohu8.com/highlight/detail?id=2490211766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490211766?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:00","pubTimestamp":1733702457,"startTime":"0","endTime":"0","summary":"根据市场公开信息及12月6日披露的机构调研信息,知名私募天算量化近期对1家上市公司进行了调研,相关名单如下:1)何氏眼科 个股亮点:公司主营业务收入主要为眼科专科诊疗服务和视光服务,目前公司实现辽宁省内地市级医院全覆盖;公司生成式人工智能应用完成chatGpt应用构建,实现问题咨询、图片设计、文档阅读理解功能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2024120900001068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2489406156","title":"何氏眼科:12月6日接受机构调研,北京英安私募、东北证券研究所等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2489406156","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489406156?lang=zh_cn&edition=full","pubTime":"2024-12-06 17:04","pubTimestamp":1733475880,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年12月6日何氏眼科发布公告称公司于2024年12月6日接受机构调研,北京英安私募朱光宇 石海吉、东北证券研究所古翰羲、天算量化孟庆辰、北京融盛私募石宇、明世伙伴私募基金何德建、众妙资本林红霞、财智聚私募宋承东、北京博润银泰尚方建、景星资产冯伟、大连航天半岛高新创投刘悦丰参与。何氏眼科主营业务:面向眼病患者提供眼科专科诊疗服务和视光服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600028369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000686","BK0183","301103","BK0028","BK0236","BK0188","BK0276"],"gpt_icon":0},{"id":"2485235293","title":"11月22日何氏眼科跌5.88%,融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485235293","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485235293?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:35","pubTimestamp":1732264531,"startTime":"0","endTime":"0","summary":"证券之星消息,11月22日何氏眼科跌5.88%,收盘报21.62元,换手率2.53%,成交量2.1万手,成交额4680.35万元。重仓何氏眼科的公募基金请见下表:根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200026274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2485710714","title":"何氏眼科(301103)11月21日主力资金净卖出402.52万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485710714","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485710714?lang=zh_cn&edition=full","pubTime":"2024-11-22 09:22","pubTimestamp":1732238573,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月21日收盘,何氏眼科报收于22.97元,下跌1.96%,换手率2.27%,成交量1.88万手,成交额4328.84万元。近5日资金流向一览见下表:何氏眼科融资融券信息显示,融资方面,当日融资买入381.93万元,融资偿还447.15万元,融资净偿还65.22万元。何氏眼科主营业务:面向眼病患者提供眼科专科诊疗服务和视光服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200008385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2485646759","title":"11月21日何氏眼科发布公告,其股东减持63.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485646759","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485646759?lang=zh_cn&edition=full","pubTime":"2024-11-21 20:01","pubTimestamp":1732190470,"startTime":"0","endTime":"0","summary":"证券之星消息,11月21日何氏眼科发布公告《何氏眼科:辽宁何氏眼科医院集团股份有限公司简式权益变动报告书》,其股东北京信中利美信股权投资中心(有限合伙)、共青城鹏信投资管理合伙企业(有限合伙)于2024年10月31日至2024年11月21日间合计减持63.84万股,占公司目前总股本的0.4039%,变动期间该股股价上涨3.56%,截止11月21日收盘报22.97元。股东增减持详情见下表:根据何氏眼科2024年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100032910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2484719486","title":"何氏眼科:11月20日接受机构调研,中金银海(香港)基金、诺泉私募基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2484719486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484719486?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:33","pubTimestamp":1732102406,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年11月20日何氏眼科发布公告称公司于2024年11月20日接受机构调研,中金银海(香港)基金雍心、诺泉私募基金吴伟、赢仕私募基金李柯兵、中国航空工业集团中航证券辽宁分公司徐秋兰、远东宏信郑镭参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000033688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2484916606","title":"何氏眼科最新公告:股东先进制造基金计划减持公司股份不超过2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484916606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484916606?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:21","pubTimestamp":1732011669,"startTime":"0","endTime":"0","summary":"何氏眼科公告,股东先进制造基金计划自本公告披露之日起十五个交易日后的三个月内通过证券交易所集中竞价和大宗交易方式减持公司股份合计不超过310.61万股,占公司剔除回购专用证券账户中股份数量后的总股本比例的2%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900030764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399260","BK0236","301103"],"gpt_icon":0},{"id":"2484915518","title":"何氏眼科(301103.SZ)股东先进制造基金拟减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2484915518","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484915518?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:11","pubTimestamp":1732011115,"startTime":"0","endTime":"0","summary":"智通财经APP讯,何氏眼科(301103.SZ)发布公告,公司于近日收到持股5%以上股东先进制造产业投资基金(有限合伙)(以下简称“先进制造基金”)出具的《关于股份减持计划的告知函》,先进制造基金计划自公告披露之日起十五个交易日后的三个月内(即2024年12月11日至2025年3月10日期间),通过证券交易所集中竞价和大宗交易方式减持公司股份合计不超过310.61万股,(占公司剔除回购专用证券账户中股份数量后的总股本比例的2%)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399260","301103","BK0236"],"gpt_icon":0},{"id":"2483920738","title":"何氏眼科:11月12日接受机构调研,中信证券、长城基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2483920738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483920738?lang=zh_cn&edition=full","pubTime":"2024-11-14 12:05","pubTimestamp":1731557122,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年11月12日何氏眼科发布公告称公司于2024年11月12日接受机构调研,中信证券徐嘉琪、长城基金梁福睿、东方红资管江琦 邹秉昂、前海开源范洁、招商基金周雨婷、嘉实基金程佳 李慧 余玉君、申万宏源证券陈田甜 田诺、景顺长城基金乔海英、华夏基金谢弘涵参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400017776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","LU1997244956.HKD","BK1564","BK0276","LU1720050803.USD","BK0012","LU0405327148.USD","BK0188","301103","BK0236","LU1064131003.USD","LU1064130708.USD","BK0196","BK0028","LU1328615791.USD","LU1997245094.SGD","LU2495084118.USD","600030","LU1997245177.USD","LU0405327494.USD","LU2148510915.USD","BK1516","LU1794554557.SGD","LU2289578879.USD","BK1147","BK1521"],"gpt_icon":1},{"id":"2481489929","title":"11月7日何氏眼科涨5.15%,融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481489929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481489929?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:23","pubTimestamp":1730967786,"startTime":"0","endTime":"0","summary":"证券之星消息,11月7日何氏眼科涨5.15%,收盘报23.9元,换手率4.78%,成交量3.97万手,成交额9327.46万元。重仓何氏眼科的公募基金请见下表:根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700026562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2480072034","title":"集采、价格战压力之下:华厦眼科白内障业务毛利率锐减 普瑞眼科、何氏眼科净利润遭脚踝斩","url":"https://stock-news.laohu8.com/highlight/detail?id=2480072034","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480072034?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:44","pubTimestamp":1730454240,"startTime":"0","endTime":"0","summary":" 近日,A股眼科医疗服务上市公司三季报披露完毕。2024年前三季度,眼科服务A股上市公司整体营收增速显著放缓,且归母净利润近五年间首次出现同比下降。其中,爱尔眼科业务毛利率同比下降0.53个百分点;华厦眼科业务毛利率同比下降1.88个百分点;普瑞眼科业务毛利率同比下降4.04个百分点;何氏眼科业务毛利率同比下降1.12个百分点。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-11-01/doc-incuqfsw6306088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301239","301267","301103"],"gpt_icon":0},{"id":"2480049160","title":"何氏眼科联合茅台招华发起一支健康科技产业基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2480049160","media":"投资界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480049160?lang=zh_cn&edition=full","pubTime":"2024-11-01 11:12","pubTimestamp":1730430720,"startTime":"0","endTime":"0","summary":"投资界消息,10月29日,何氏眼科发布公告,公司与深圳市招商国协贰号股权投资基金管理有限公司及茅台招华(贵州)产业发展基金合伙企业共同投资设立招华(贵州)健康科技产业发展基金合伙企业。基金规模7.97亿元,招商局资本担任基金管理人。基金以眼健康为切入点,主要投资于新一代医疗健康、食疗营养以及合成生物等领域。官网显示,何氏眼科创办于1995年,是集医教研于一体,采用三级眼健康医疗服务模式的集团型连锁眼科服务机构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101114808ab8f8326&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101114808ab8f8326&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0577902371.SGD","301103","LU0594300179.USD","BK0187","LU0651946864.USD","LU0650527681.SGD","LU0348825331.USD","LU0072913022.USD","LU0823426308.USD","LU0516423174.USD","LU0880133367.SGD","BK0028","LU0326950275.SGD","LU0039217434.USD","LU0456827905.SGD","LU0516422366.SGD","LU0052750758.USD","LU0577902298.EUR","LU0577902454.USD","LU0873338254.USD","LU0211977185.USD","LU0048580855.USD","LU0456846285.SGD","LU0348816934.USD","LU0348814723.USD","LU0348805143.USD","LU0577902538.SGD","BK0236","LU0359202008.SGD","LU0231483743.USD","LU0051755006.USD","LU0320764599.SGD","LU0328353924.USD","LU0708995583.HKD","LU0067412154.USD","LU0327786744.USD","LU0516422952.EUR","LU0572944931.SGD","LU0516423091.SGD","LU0501845795.SGD","BK0196","LU0878005551.USD","600519","LU0307460666.USD","LU0405327494.USD","LU0370786039.SGD","LU0516422440.USD","LU0228659784.USD","IE00BMCWC346.EUR","BK0012"],"gpt_icon":0},{"id":"2479261285","title":"何氏眼科(301103)2024年三季报简析:净利润减83.53%,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479261285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479261285?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:35","pubTimestamp":1730241335,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期何氏眼科发布2024年三季报。截至本报告期末,公司营业总收入8.65亿元,同比下降8.4%,归母净利润1637.55万元,同比下降83.53%。按单季度数据看,第三季度营业总收入2.8亿元,同比下降13.32%,第三季度归母净利润-768.85万元,同比下降136.5%。本报告期何氏眼科应收账款上升,应收账款同比增幅达71.21%。去年的净利率为4.88%,算上全部成本后,公司产品或服务的附加值不高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000007410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103"],"gpt_icon":0},{"id":"2479478898","title":"何氏眼科:拟认缴出资2.4亿元,与茅台招华产业基金等合作设立投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2479478898","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479478898?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:26","pubTimestamp":1730193968,"startTime":"0","endTime":"0","summary":"近日,何氏眼科发布关于与专业投资机构共同投资基金的公告。披露为充分利用专业投资机构在投资并购领域的广泛布局及资源整合能力,促进公司未来发展,以眼健康为切入点,加快新一代医疗健康等领域布局,公司召开第三届董事会第九次会议,审议通过了《关于与专业投资机构共同投资基金的议案》。同意公司与深圳市招商国协贰号股权投资基金管理有限公司及茅台招华(贵州)产业发展基金合伙企业(有限合伙)共同投资设立招华(贵州)健康科技产业发展基金合伙企业(有限合伙)。合伙企业认缴出资总额7.97亿元人民币,其中,公司拟以自有资金认缴出资2.4亿元人民币作为有限合伙人。(企业公告)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029172819ab7e50b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029172819ab7e50b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0328353924.USD","600519","BK0183","BK0015","LU0348814723.USD","LU0039217434.USD","LU0605514214.HKD","LU0181495838.USD","IE00BYV24P56.USD","LU0140636845.USD","LU0072913022.USD","LU0516422366.SGD","LU0359202008.SGD","LU0307460666.USD","LU0577902454.USD","LU0823426308.USD","LU0516422952.EUR","LU0456846285.SGD","LU0572944931.SGD","IE00BMCWC346.EUR","LU0348805143.USD","LU0880133367.SGD","BK0012","LU0516423174.USD","LU0405327148.USD","BK0188","LU0577902298.EUR","LU0878005551.USD","301103","BK0236","LU0067412154.USD","LU0823426480.USD","LU0516422440.USD","LU0651946864.USD","LU0456827905.SGD","LU0650527681.SGD","LU0359201612.USD","LU0326950275.SGD","LU0348825331.USD","LU0588546209.SGD","LU0417516902.SGD","LU0084288322.USD","BK0187","LU0320764599.SGD","LU0594300179.USD","LU0405327494.USD","LU0231483743.USD","LU0211977185.USD","LU0501845795.SGD","LU0051755006.USD"],"gpt_icon":0},{"id":"2479427420","title":"何氏眼科(301103)9月30日股东户数1万户,较上期增加3.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479427420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479427420?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:21","pubTimestamp":1730193677,"startTime":"0","endTime":"0","summary":"证券之星消息,近日何氏眼科披露,截至2024年9月30日公司股东户数为9969.0户,较6月30日增加319.0户,增幅为3.31%。在医疗服务行业个股中,何氏眼科股东户数低于行业平均水平,截至9月30日,医疗服务行业平均股东户数为4.5万户。从股价来看,2024年6月30日至2024年9月30日,何氏眼科区间涨幅为14.12%,在此期间股东户数增加319.0户,增幅为3.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900031768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2479430255","title":"图解何氏眼科三季报:第三季度单季净利润同比减136.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479430255","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479430255?lang=zh_cn&edition=full","pubTime":"2024-10-29 01:42","pubTimestamp":1730137326,"startTime":"0","endTime":"0","summary":"证券之星消息,何氏眼科2024年三季报显示,公司主营收入8.65亿元,同比下降8.4%;归母净利润1637.55万元,同比下降83.53%;扣非净利润1478.94万元,同比下降84.57%;其中2024年第三季度,公司单季度主营收入2.8亿元,同比下降13.32%;单季度归母净利润-768.85万元,同比下降136.5%;单季度扣非净利润-956.67万元,同比下降144.47%;负债率16.37%,投资收益0.07万元,财务费用-392.71万元,毛利率40.92%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900001178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103"],"gpt_icon":0},{"id":"2479143416","title":"何氏眼科(301103.SZ)发布前三季度业绩,净利润1637.55万元,下降83.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479143416","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479143416?lang=zh_cn&edition=full","pubTime":"2024-10-29 00:59","pubTimestamp":1730134747,"startTime":"0","endTime":"0","summary":"智通财经APP讯,何氏眼科(301103.SZ)发布2024年三季度报告,该公司前三季度营业收入为8.65亿元,同比减少8.40%。归属于上市公司股东的净利润为1637.55万元,同比减少83.53%。归属于上市公司股东的扣除非经常性损益的净利润为1478.94万元,同比减少84.57%。基本每股收益为0.1045元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301103"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-22","address":"辽宁省沈阳市浑南区天赐街5-1号(607)","stockEarnings":[{"period":"1week","weight":-0.0977},{"period":"1month","weight":-0.0475},{"period":"3month","weight":0.2846},{"period":"6month","weight":0.0247},{"period":"1year","weight":-0.2335},{"period":"ytd","weight":-0.2419}],"companyName":"辽宁何氏眼科医院集团股份有限公司","boardCode":"AI0083","perCapita":"8334股","boardName":"卫生","registeredCapital":"15802万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 辽宁何氏眼科医院集团股份有限公司主营业务为面向眼病患者提供眼科专科诊疗服务和视光服务。公司的主要服务项目有白内障诊疗服务项目、屈光不正诊疗服务项目、玻璃体视网膜诊疗服务项目青光眼诊疗服务项目、干眼特色诊疗服务项目、中医特色诊疗服务项目。沈阳何氏眼科医院被评为“国家临床重点专科”、国际眼科理事会眼科专科医师培训基地、国家药物临床试验机构。","serverTime":1734698168400,"listedPrice":42.5,"stockholders":"9969人(较上一季度增加3.31%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"何氏眼科,301103,何氏眼科股票,何氏眼科股票老虎,何氏眼科股票老虎国际,何氏眼科行情,何氏眼科股票行情,何氏眼科股价,何氏眼科股市,何氏眼科股票价格,何氏眼科股票交易,何氏眼科股票购买,何氏眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}